New drugs in acute myeloid leukemia

被引:83
作者
Kadia, T. M. [1 ]
Ravandi, F. [1 ]
Cortes, J. [1 ]
Kantarjian, H. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
acute myeloid leukemia; new therapies; FLT3; inhibitors; BCL2; inhibitor; monoclonal antibodies; targeted therapy; HIGH-DOSE DAUNORUBICIN; PHASE I/II TRIAL; OLDER PATIENTS; GEMTUZUMAB OZOGAMICIN; ADULT PATIENTS; KINASE INHIBITOR; MYELODYSPLASTIC SYNDROME; INDUCTION CHEMOTHERAPY; INTENSIVE CHEMOTHERAPY; HYPOMETHYLATING AGENT;
D O I
10.1093/annonc/mdw015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Standard treatment for acute myeloid leukemia has changed little in the past 40 years. New cytotoxic agents, targeted small-molecule inhibitors, and monoclonal antibodies are currently in advanced development to improve on standard approaches.The standard therapy for acute myeloid leukemia (AML) has not changed meaningfully for the past four decades. Improvements in supportive care and modifications to the dose and schedule of existing agents have led to steady improvements in outcomes. However, developing new therapies for AML has been challenging. Although there have been advances in understanding the biology of AML, translating this knowledge to viable treatments has been slow. Active research is currently ongoing to address this important need and several promising drug candidates are currently in the pipeline. Here, we review some of the most advanced and promising compounds that are currently in clinical trials and may have the potential to be part of our future armamentarium. These drug candidates range from cytotoxic chemotherapies, targeted small-molecule inhibitors, and monoclonal antibodies.
引用
收藏
页码:770 / 778
页数:9
相关论文
共 82 条
[21]   Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia [J].
Dennis, Mike ;
Russell, Nigel ;
Hills, Robert K. ;
Hemmaway, Claire ;
Panoskaltsis, Nicki ;
McMullin, Mary-Frances ;
Kjeldsen, Lars ;
Dignum, Helen ;
Thomas, Ian F. ;
Clark, Richard E. ;
Milligan, Don ;
Burnett, Alan K. .
BLOOD, 2015, 125 (19) :2923-2932
[22]  
DiNardo CdBS., 2015, Blood
[23]   Acute Myeloid Leukemia [J].
Doehner, Hartmut ;
Weisdorf, Daniel J. ;
Bloomfield, Clara D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (12) :1136-1152
[24]   Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy [J].
Doehner, Hartmut ;
Luebbert, Michael ;
Fiedler, Walter ;
Fouillard, Loic ;
Haaland, Alf ;
Brandwein, Joseph M. ;
Lepretre, Stephane ;
Reman, Oumedaly ;
Turlure, Pascal ;
Ottmann, Oliver G. ;
Mueller-Tidow, Carsten ;
Kraemer, Alwin ;
Raffoux, Emmanuel ;
Doehner, Konstanze ;
Schlenk, Richard F. ;
Voss, Florian ;
Taube, Tillmann ;
Fritsch, Holger ;
Maertens, Johan .
BLOOD, 2014, 124 (09) :1426-1433
[25]   Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet [J].
Doehner, Hartmut ;
Estey, Elihu H. ;
Amadori, Sergio ;
Appelbaum, Frederick R. ;
Buechner, Thomas ;
Burnett, Alan K. ;
Dombret, Herve ;
Fenaux, Pierre ;
Grimwade, David ;
Larson, Richard A. ;
Lo-Coco, Francesco ;
Naoe, Tomoki ;
Niederwieser, Dietger ;
Ossenkoppele, Gert J. ;
Sanz, Miguel A. ;
Sierra, Jorge ;
Tallman, Martin S. ;
Loewenberg, Bob ;
Bloomfield, Clara D. .
BLOOD, 2010, 115 (03) :453-474
[26]   International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts [J].
Dombret, Herve ;
Seymour, John F. ;
Butrym, Aleksandra ;
Wierzbowska, Agnieszka ;
Selleslag, Dominik ;
Jang, Jun Ho ;
Kumar, Rajat ;
Cavenagh, James ;
Schuh, Andre C. ;
Candoni, Anna ;
Recher, Christian ;
Sandhu, Irwindeep ;
Bernal del Castillo, Teresa ;
Al-Ali, Haifa Kathrin ;
Martinelli, Giovanni ;
Falantes, Jose ;
Noppeney, Richard ;
Stone, Richard M. ;
Minden, Mark D. ;
McIntyre, Heidi ;
Songer, Steve ;
Lucy, Lela M. ;
Beach, C. L. ;
Doehner, Hartmut .
BLOOD, 2015, 126 (03) :291-299
[27]   Metabolism of (+)-1,4-Dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acid (Voreloxin; Formerly SNS-595), a Novel Replication-Dependent DNA-Damaging Agent [J].
Evanchik, Marc J. ;
Allen, Darin ;
Yoburn, Josh C. ;
Silverman, Jeffrey A. ;
Hoch, Ute .
DRUG METABOLISM AND DISPOSITION, 2009, 37 (03) :594-601
[28]   First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia [J].
Feldman, Eric J. ;
Lancet, Jeffrey E. ;
Kolitz, Jonathan E. ;
Ritchie, Ellen K. ;
Roboz, Gail J. ;
List, Alan F. ;
Allen, Steven L. ;
Asatiani, Ekatherine ;
Mayer, Lawrence D. ;
Swenson, Christine ;
Louie, Arthur C. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) :979-985
[29]   Anthracycline Dose Intensification in Acute Myeloid Leukemia [J].
Fernandez, Hugo F. ;
Sun, Zhuoxin ;
Yao, Xiaopan ;
Litzow, Mark R. ;
Luger, Selina M. ;
Paietta, Elisabeth M. ;
Racevskis, Janis ;
Dewald, Gordon W. ;
Ketterling, Rhett P. ;
Bennett, John M. ;
Rowe, Jacob M. ;
Lazarus, Hillard M. ;
Tallman, Martin S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (13) :1249-1259
[30]   Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3 [J].
Fischer, Thomas ;
Stone, Richard M. ;
DeAngelo, Daniel J. ;
Galinsky, Ilene ;
Estey, Elihu ;
Lanza, Carlo ;
Fox, Edward ;
Ehninger, Gerhard ;
Feldman, Eric J. ;
Schiller, Gary J. ;
Klimek, Virginia M. ;
Nimer, Stephen D. ;
Gilliland, D. Gary ;
Dutreix, Catherine ;
Huntsman-Labed, Alice ;
Virkus, Jodi ;
Giles, Francis J. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) :4339-4345